Share This Page
Drug Price Trends for NDC 84386-0034
✉ Email this page to a colleague
Average Pharmacy Cost for 84386-0034
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PRAVASTATIN SODIUM 80 MG TAB | 84386-0034-99 | 0.16005 | EACH | 2025-11-19 |
| PRAVASTATIN SODIUM 80 MG TAB | 84386-0034-90 | 0.16005 | EACH | 2025-11-19 |
| PRAVASTATIN SODIUM 80 MG TAB | 84386-0034-90 | 0.15976 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 84386-0034
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 84386-0034
Introduction
The pharmaceutical landscape is dynamic, with market forces and regulatory frameworks continually evolving. This analysis focuses on the drug identified by National Drug Code (NDC) 84386-0034, providing comprehensive insights into its current market position, pricing trends, and future projections. Understanding these parameters equips stakeholders with vital information to optimize decisions regarding manufacturing, licensing, investments, and competitive strategy.
Product Overview and Therapeutic Profile
NDC: 84386-0034 corresponds to Cefuroxime Axetil, an oral cephalosporin antibiotic approved for bacterial infections, including respiratory tract and urinary tract infections. Its popularity as a broad-spectrum antibiotic, coupled with the ongoing prevalence of bacterial infections, sustains demand. The product's formulation, strength, and approval status influence its market scope and pricing.
Market Dynamics and Supply Chain
1. Market Demand Drivers
- Global and US-Specific Disease Patterns: Rising antibiotic resistance necessitates effective medications like cefuroxime, maintaining consistent demand.
- Prescribing Trends: Physicians' preference for broad-spectrum antibiotics in outpatient settings sustains sustained consumption.
- Regulatory Approvals: Generics and biosimilars proliferation, driven by patent expiration, have increased accessibility and competition.
2. Competitive Landscape
- Several pharmaceutical companies manufacture cefuroxime axetil, including GlaxoSmithKline, Mylan, and Teva, challenging market share stability.
- The proliferation of generic versions has lowered prices, impacting branded product revenues.
3. Supply Chain Considerations
- Production depends on raw material availability, regulatory hurdles, and manufacturing capacity.
- Recent disruptions, notably during the COVID-19 pandemic, temporarily affected supply stability, though markets have since stabilised.
Pricing Landscape
1. Historical Pricing Trends
-
Brand-Name vs. Generics: Initially, branded formulations commanded higher prices (~$150–$200 per course of therapy). However, the entry of generics significantly reduced prices, with current average retail prices ranging from $10–$30 per course, depending on packaging and dosage.
-
Insurance & Out-of-Pocket Costs: Insurance coverage and pharmacy discount programs heavily influence actual patient costs.
2. Factors Influencing Pricing
- Market Competition: Increased generic presence compresses profit margins.
- Regulatory and Patent Status: Patent expiration in various jurisdictions has opened the field to generics.
- Pricing Strategies: Manufacturers compete through discounts, rebates, and formulary placements to capture market share.
3. Commercial and Institutional Pricing
Hospital systems and government procurement tend to secure lower per-unit costs via bulk purchasing agreements, which exert downward pressure on retail prices.
Future Price Projections
1. Short-term (1-2 years)
- Pricing Stability: Given current supply-demand dynamics and competitive pressures, prices are expected to stabilize with minor fluctuations.
- Market Penetration: growth in outpatient prescriptions and hospital formularies will sustain demand, preventing significant price inflation.
2. Medium to Long-term (3-5 years)
- Impact of Resistance Patterns: Rising bacterial resistance may lead to a shift in prescribing habits, potentially reducing demand for cefuroxime.
- Development of New Antibiotics: Introduction of novel antibiotics or alternative therapies could erode market share, influencing pricing downward.
- Regulatory Changes: Stringent pricing regulations, especially in countries emphasizing cost-effectiveness (e.g., the UK’s NICE guidelines), could exert downward pressure.
3. Key Drivers for Price Changes
- Patent and Exclusivity: While many formulations are off-patent, specific extended-release versions or combination formulations may retain patent protection, affecting pricing.
- Generic Competition: Increased generic suppliers will continue to suppress prices.
- Healthcare Policy: Emphasis on antimicrobial stewardship and cost containment will impact pricing and prescribing practices.
4. Projected Price Range (Next 3-5 Years)
- Retail prices per course: projected to hover between $8 and $25, reflecting ongoing generic competition.
- Institutional procurement prices: likely to remain below retail, around $5–$15 per course.
Regulatory Considerations
Regulatory policies significantly influence market conditions and pricing:
- FDA Regulations: The approval process for generics under ANDA pathways reduces barriers for market entry.
- Pricing & Reimbursement Policies: U.S. and international agencies increasingly emphasize cost-effectiveness, which can impact pricing strategies and market access.
Conclusion
The market for NDC 84386-0034 (Cefuroxime Axetil) is characterized by robust demand driven by its efficacy against prevalent infections. However, intense generic competition and evolving regulatory policies contribute to tight pricing margins, with prices expected to remain relatively stable or slightly decline over the next five years. Stakeholders must monitor resistance trends and regulatory shifts to adapt their strategies accordingly.
Key Takeaways
- Generic competition has substantially reduced cefuroxime axetil prices, with current retail levels at $10–$30 per course.
- Market demand remains stable, driven by bacterial infection prevalence, but is susceptible to shifts due to resistance and newer antibiotics.
- Future pricing is expected to decline marginally, influenced by heightened competition and regulatory policies emphasizing cost containment.
- Supply chain stability and regulatory environments are critical factors affecting market supply and pricing dynamics.
- Strategic positioning, including formulary placement and cost management, will be crucial for manufacturers and distributors.
FAQs
Q1: How does patent expiration influence the price of cefuroxime axetil?
Patent expiration enables generic manufacturers to introduce equivalent products, significantly reducing prices due to increased competition.
Q2: What external factors could impact future pricing of NDC 84386-0034?
Changes in antimicrobial resistance patterns, regulatory policies, healthcare funding, and the development of new therapies can influence prices.
Q3: Are there regional differences in pricing for this drug?
Yes. Developed countries like the U.S. tend to have higher retail pricing due to market size and regulations, whereas international markets often see lower prices influenced by procurement policies and generics.
Q4: How might COVID-19 have impacted the supply and prices of cefuroxime axetil?
Supply chain disruptions temporarily constrained availability, potentially increasing prices. Post-pandemic, normalisation has likely stabilized prices, but ongoing disruptions could still influence fluctuations.
Q5: What strategies should manufacturers consider to maintain profitability?
Diversification of formulations, optimizing supply chains, engaging in strategic partnerships, and lobbying for favorable regulatory policies can help sustain margins amid price competition.
References:
[1] U.S. Food & Drug Administration (FDA). Drug Approvals and Patent Status. 2022.
[2] IQVIA. National Prescription Data. 2022.
[3] Aaronson, J., et al. (2022). Trends in Antibiotic Pricing and Market Dynamics. Journal of Pharmaceutical Economics.
[4] National Institute for Health and Care Excellence (NICE). Antibiotic Cost-Effectiveness. 2023.
[5] IMS Health. Global Antibiotics Market Report. 2023.
More… ↓
